Summit Therapeutics plc
(‘Summit’ or the ‘Company’)Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2019 on 11 October 2019Oxford, UK, and Cambridge, MA, US, 10 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the second quarter and half year ended 31 July 2019 on 11 October 2019.Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release, and a replay of the call will also be available through the Company’s website, www.summitplc.com.About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.Contacts-END-
Bay Street News